Skip to main navigation menu Skip to main content Skip to site footer

Vol. 12 No. 12 (2025)
International Multidisciplinary Journal for Research & Development

Articles

EFFECTIVENESS OF IMMUNOMODULATORY THERAPY IN VIRAL INFECTIONS.

Published 2025-12-21

  • G’ulomjonova Ziyodahon

G’ulomjonova Ziyodahon
Kokand State University, Andijan Branch Field of Study: General Medicine (Therapeutics), Group 23-02 Student

Abstract

Viral infections remain a major global health concern, causing significant morbidity and mortality across all age groups. Immunomodulators, which regulate and enhance the body’s immune response, have emerged as a promising therapeutic approach in managing viral diseases. This article reviews the efficacy of various immunomodulatory agents in the treatment and prevention of viral infections, including interferons, cytokine modulators, and novel biologic therapies. Clinical studies demonstrate that immunomodulators can reduce viral replication, enhance antiviral immune responses, and improve patient outcomes when used as adjunctive therapy. However, the effectiveness of these agents depends on factors such as the type of virus, timing of administration, dosage, and patient-specific characteristics. The review emphasizes the need for personalized treatment strategies and continuous research to optimize the use of immunomodulators in viral infections.

Keywords

Viral infections, immunomodulators, immune response, interferons, cytokine therapy, antiviral therapy, treatment efficacy.

PDF

References

  1. Kotenko, S.V., & Durbin, J.E. Interferons: signaling, antiviral and immune functions. Nature Reviews Immunology. 2017;17(7):441–456.
  2. Samuel, C.E. Antiviral actions of interferons. Clinical Microbiology Reviews. 2001;14(4):778–809.
  3. Schoenborn, J.R., & Wilson, C.B. Regulation of interferon-gamma during innate and adaptive immune responses. Advances in Immunology. 2007;96:41–101.
  4. Arvin, A.M., et al. Immunomodulators in the treatment of viral infections. The Journal of Infectious Diseases. 2013;208(Suppl 2):S107–S114.
  5. Crotta, S., et al. Type I and Type III interferons: induction, signaling, and antiviral activities. Nature Reviews Immunology. 2013;13:227–239.
  6. Channappanavar, R., & Perlman, S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Seminars in Immunopathology. 2017;39:529–539.
  7. Dinarello, C.A. Immunomodulatory therapies for viral infections: cytokine inhibitors. Nature Reviews Drug Discovery. 2018;17:739–756.
  8. Kawai, T., & Akira, S. Toll-like receptors and their crosstalk with other innate receptors in antiviral immunity. Immunity. 2011;34(5):637–650.
  9. McNab, F., et al. Type I interferons in infectious disease. Nature Reviews Immunology. 2015;15:87–103.
  10. Fenton, C., & Sadler, A.J. Therapeutic applications of type I interferons. Trends in Molecular Medicine. 2016;22(2):135–147.
  11. Li, J., et al. Monoclonal antibodies as immunomodulators in viral infections. Frontiers in Immunology. 2020;11:1022.
  12. Bhattacharya, S., et al. Cytokine-based therapy for viral infections: recent advances. Current Opinion in Virology. 2019;34:100–110.
  13. Zhang, W., et al. Immune modulation in viral infections: strategies and clinical applications. Expert Review of Clinical Immunology. 2021;17(9):925–941.
  14. Chen, N., et al. Immunomodulatory therapy for COVID-19: current evidence and perspectives. Frontiers in Immunology. 2021;12:642770.
  15. Iwasaki, A., & Medzhitov, R. Control of adaptive immunity by the innate immune system. Nature Immunology. 2015;16:343–353.

Downloads

Download data is not yet available.